*2.2. Drugs*

The prototype bicyclam CXCR4 inhibitor and agonist stromal derived factor (SDF-1alpha) AMD3100, (1-1\*-[1,4-phenylenebis(methylene)]-bis(1,4,8,11-tetraazacyclotetradecane) octahydrochloride dihydrate]) synthesized at Johnson Matthey [48–50], and the CCR5 inhibitor, N,N-dimethyl-N-[4-[[[2-(4-methylphenyl) -6,7-dihydro-5H-benzocyclohepten-8-yl] carbonil]amino]benzyl] tetrahydro-2H-pyran-4-aminium chloride (TAK779), a nonpeptide compound with a small molecular weight (Mr 531.13), (Takeda Chemical Industries, Ltd., Osaka, Japan) [51,52], were suspended and aliquoted in Phosphate-bu ffered saline (PBS) solution, and used to 5 μM and 2 and 10 μg/mL, respectively.
